CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published ahead of print on August 9, 2006
Clin J Am Soc Nephrol 1: 1080-1089, 2006
© 2006 American Society of Nephrology
doi: 10.2215/CJN.01800506
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.01800506v1
1/5/1080    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Augustine, J. J.
Right arrow Articles by Hricik, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Augustine, J. J.
Right arrow Articles by Hricik, D. E.

In-Depth Reviews

Steroid Sparing in Kidney Transplantation: Changing Paradigms, Improving Outcomes, and Remaining Questions

Joshua J. Augustine, and Donald E. Hricik

Department of Medicine, Case Western Reserve University, and Division of Nephrology and Hypertension, University Hospitals of Cleveland, Cleveland, Ohio

Address correspondence to: Dr. Donald E. Hricik, University Hospitals of Cleveland, 11100 Euclid Avenue, Room 8124 Lakeside Building, Cleveland, OH 44106. Phone: 216-844-8060; Fax: 216-844-5204; dhricik{at}aol.com

The widely known adverse effects of long-term therapy with corticosteroids have motivated increasing interest in steroid-free immunosuppression for kidney transplant recipients. Results from recent trials that used newer immunosuppressants to facilitate elimination of steroids suggest better short-term results than were achieved in an earlier era. However, the best results have been reported in uncontrolled trials of low-risk patients or in randomized trials with relatively short periods of follow-up. Increasingly, the therapeutic paradigm has shifted from late withdrawal of steroids to very early withdrawal after transplantation or even complete avoidance. Induction antibody therapy has been used routinely in the most successful trials that involved early steroid withdrawal or avoidance. Although the outcomes of kidney transplant recipients who are treated with steroid-free immunosuppression are improving steadily, there still is room for concern in recommending this strategy as a standard of practice.




This article has been cited by other articles:


Home page
 DiabetesHome page
J. Tan, S. Yang, J. Cai, J. Guo, L. Huang, Z. Wu, J. Chen, and L. Liao
Simultaneous Islet and Kidney Transplantation in Seven Patients With Type 1 Diabetes and End-Stage Renal Disease Using a Glucocorticoid-Free Immunosuppressive Regimen With Alemtuzumab Induction
Diabetes, October 1, 2008; 57(10): 2666 - 2671.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. Lam, N. Partovi, L. S. Ting, and M. H. Ensom
Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction?
Ann. Pharmacother., July 1, 2008; 42(7): 1037 - 1047.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Chadban
New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1816 - 1818.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Nephrology.